A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer

Histologically or cytologically-proven new diagnosis of single primary bronchogenic Stage IIIA or selected Stage IIIB NSCLC. PET scan within 42 days prior. Must have measurable or non-measurable disease. Measurable diseased must be assessed by chest CT, MRI or x-ray and CT of upper abdomen within 28 days prior. Non-measurable disease must be assessed within 42 days prior. No brain mets. CT/MRI of brain within 42 days prior. Zubrod 0-2. Pulmonary function tests within 42 days prior. See related criteria in section 5.7. Pts must not have malignant pleural effusion. Pts with non-malignant pleural effusion must meet one of the criteria in Section 5.8. No prior chemo or curative surgery for this cancer. No prior radiation. No therapy that specifically targets EGFR pathway. Within 28 days prior: ANC >/= 1,500/mcl; Platelets >/=100,000/mcl; Serum creatinine </= 1.5xIULN; Serum bilirubin </= IULN; SGOT or SGPT </= 2.5xIULN; Alkaline phosphatase </= IULN unless SGOT or SGPT is </= IULN, in which case alkaline phosphatase must be </= 4xIULN. Must be willing to provide smoking history. Must have IRB approval of S9925 and patients must be offered participation in S9925. Patients must not have any of the conditions listed in Section 5.15. No pregnant or nursing women.